Compare SPFI & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SPFI | DSGN |
|---|---|---|
| Founded | 1941 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 794.2M | 853.8M |
| IPO Year | 2019 | 2021 |
| Metric | SPFI | DSGN |
|---|---|---|
| Price | $44.75 | $12.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $46.00 | $15.25 |
| AVG Volume (30 Days) | 144.1K | ★ 636.8K |
| Earning Date | 04-28-2026 | 04-28-2026 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | ★ 17.81 | N/A |
| EPS | ★ 0.85 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.65 | N/A |
| Revenue Next Year | $9.40 | N/A |
| P/E Ratio | $52.56 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $35.34 | $3.85 |
| 52 Week High | $46.94 | $17.25 |
| Indicator | SPFI | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 55.53 | 47.48 |
| Support Level | $39.06 | $11.65 |
| Resistance Level | $44.48 | $13.54 |
| Average True Range (ATR) | 1.37 | 0.82 |
| MACD | 0.02 | -0.10 |
| Stochastic Oscillator | 48.38 | 32.14 |
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking. The majority of the company's revenues is derived from interest income and other sources, including loans, securities and derivatives.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.